- Home
- TASK vs XERS Comparison
TASK vs XERS Comparison
Compare TASK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TASK | XERS |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.3M | 965.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TASK | XERS |
|---|---|---|
| Price | $10.38 | $5.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $14.90 | $10.43 |
| AVG Volume (30 Days) | 684.1K | ★ 2.2M |
| Earning Date | 05-26-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 100.00 |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $6.12 | $28.65 |
| Revenue Next Year | $6.77 | $18.33 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $9.55 | $3.81 |
| 52 Week High | $18.39 | $10.08 |
Technical Indicators
Market Signals| Indicator | TASK | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 27.69 |
| Support Level | $9.78 | $4.30 |
| Resistance Level | $11.76 | $7.21 |
| Average True Range (ATR) | 0.49 | 0.36 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 27.27 | 6.21 |
Price Performance
Historical ComparisonAbout TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.